Product Information
IRBESARTAN 300 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.1623 per EA under NDC 33342004907. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Oct 3, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342004907
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IRBESARTANApproval Type
Generic (ANDA)
FDA Application
ANDA202254FDA Approved
10/3/2012
TE Code
AB
On Market Since
9/27/2012
Pharmacological Classes
Price Statistics
The NADAC for IRBESARTAN 300 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 53.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1623 per EA |
|---|---|
| All-time high | $0.3794 (Jun 10, 2020) |
| All-time low | $0.1461 (Feb 18, 2026) |
| 52-week high | $0.1623 |
| 52-week low | $0.1461 |
| Median price | $0.2663 |
| Average price | $0.2613 |
| Largest weekly change | +33.1% (Aug 21, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Irbesartan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IRBESARTAN 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN 300 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $0.1623 per EA (NDC 33342004907), effective Sep 30, 2026.
How has the price of IRBESARTAN 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for IRBESARTAN 300 MG TABLET has declined 53.7%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for IRBESARTAN 300 MG TABLET?
Since Nov 28, 2013, the NADAC for IRBESARTAN 300 MG TABLET has ranged from a low of $0.1461 (Feb 18, 2026) to a high of $0.3794 (Jun 10, 2020), with a median of $0.2663 per EA.
Are there cheaper alternatives to IRBESARTAN 300 MG TABLET?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IRBESARTAN 300 MG TABLET, is $0.1555 per EA — about 4% below IRBESARTAN 300 MG TABLET.
Who manufactures IRBESARTAN 300 MG TABLET?
IRBESARTAN 300 MG TABLET (NDC 33342004907) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.